Clinical Trials

149 enrolled

Multiple Myeloma

NCT04973605 2026-05-11

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

246 enrolled

Multiple Myeloma

NCT05535244 2026-05-07

CAMMA 2

90 enrolled

Multiple Myeloma

NCT04126200 2026-05-06

DREAMM 5

208 enrolled 5 charts

Multiple Myeloma

NCT05850234 2026-05-06

DURGA-1

182 enrolled

Multiple Myeloma

NCT07084896 2026-05-06

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

106 enrolled 32 charts

Multiple Myeloma

NCT02343042 2026-05-04

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT04083534 2026-05-04

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

43 enrolled

Multiple Myeloma

NCT06292780 2026-04-29

LINKER-AL2

220 enrolled

Multiple Myeloma, Recurrence

NCT03761108 2026-04-20

LINKER-MM1

387 enrolled 1 FDA

Multiple Myeloma, Recurrence

NCT07455851 2026-04-15

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

150 enrolled

Multiple Myeloma

NCT06669247 2026-04-13

COSTIMM

186 enrolled

Multiple Myeloma

NCT07523555 2026-04-13

ADAPT-HEM

LymphoidMyeloidOther hematologic neoplasmPlasma cell

96 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Leukemia, Plasma Cell, Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07510100 2026-04-03

FUMANBA-04

17 enrolled

Multiple Myeloma, Recurrence

NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

LymphoidMyeloidOther hematologic neoplasmPlasma cell

606 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

466 enrolled 57 charts

Multiple Myeloma, Recurrence

NCT01615029 2026-03-16

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

45 enrolled 14 charts

Multiple Myeloma, Recurrence

NCT07454187 2026-03-06

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

40 enrolled

Multiple Myeloma

NCT06235229 2026-02-25

DURGA-3

110 enrolled

Multiple Myeloma

NCT07336472 2026-02-25

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

360 enrolled

Multiple Myeloma

NCT07421856 2026-02-19

Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.

24 enrolled

Multiple Myeloma

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

440 enrolled

Multiple Myeloma, Neoplasms

NCT03374085 2026-02-09

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

200 enrolled

Multiple Myeloma, Recurrence

NCT03933735 2026-02-06

A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

220 enrolled

Multiple Myeloma

NCT05590377 2026-01-30

iinnovate-3

15 enrolled 12 charts

Multiple Myeloma

NCT03215030 2026-01-29

iinnovate-1

272 enrolled 67 charts

Multiple Myeloma

NCT04586426 2026-01-16

RedirecTT-1

228 enrolled

Multiple Myeloma

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

LymphoidOther hematologic neoplasmPlasma cell

250 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT02328014 2025-12-09

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

40 enrolled 12 charts

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT06049290 2025-12-04

A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

342 enrolled

Multiple Myeloma

NCT03837509 2025-11-04

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

15 enrolled 15 charts

Multiple Myeloma, Recurrence

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

320 enrolled 35 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT04582539 2025-10-22

LIMBER

Classical hematologyMyeloidPlasma cell

22 enrolled 28 charts

Anemia, Multiple Myeloma, Myelodysplastic Syndromes

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

137 enrolled 31 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT07217119 2025-10-15

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

25 enrolled

Multiple Myeloma

NCT07217184 2025-10-15

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

30 enrolled

Phase 1/2 Enrolling by invitation

Multiple Myeloma

NCT07210047 2025-10-07

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

21 enrolled

Multiple Myeloma

NCT07107204 2025-09-17

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

LymphoidOther hematologic neoplasmPlasma cell

116 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT04855136 2025-09-11

KarMMa-7

21 enrolled

Multiple Myeloma

NCT05372354 2025-09-05

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

260 enrolled

Multiple Myeloma

NCT07150091 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

20 enrolled

Multiple Myeloma

NCT07150104 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

14 enrolled